DNLI - Denali Therapeutics Inc Stock Price, Fair Value and News

19.76USD+0.46 (+2.38%)Market Closed

Market Summary

USD19.76+0.46

Market Closed

2.38%

DNLI Alerts

Losses in recent quarter

DNLI Stock Price

View Fullscreen

DNLI RSI Chart

DNLI Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

-20.53

Price/Sales (Trailing)

8.53

Price/Free Cashflow

-6.63

DNLI Price/Sales (Trailing)

DNLI Profitability

Return on Equity

-9.43%

Return on Assets

-8.68%

Free Cashflow Yield

-15.09%

DNLI Fundamentals

DNLI Revenue

Revenue (TTM)

330.5M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

DNLI Earnings

Earnings (TTM)

-137.2M

Earnings Growth (Yr)

7.27%

Earnings Growth (Qtr)

14.79%

Breaking Down DNLI Revenue

Last 7 days

17.3%

Last 30 days

8.2%

Last 90 days

10.5%

Trailing 12 Months

-38.3%

How does DNLI drawdown profile look like?

DNLI Financial Health

Current Ratio

11.79

DNLI Investor Care

Shares Dilution (1Y)

4.18%

Diluted EPS (TTM)

-0.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	101.5M	343.1M	340.8M	330.5M
2022	82.9M	112.4M	110.7M	108.5M
2021	263.9M	192.2M	120.4M	48.7M
2020	26.1M	27.7M	23.5M	335.7M
2019	103.5M	77.9M	52.3M	26.7M
2018	0	0	0	129.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Denali Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	sato vicki l	sold	-30,471	18.29	-1,666	-
Apr 01, 2024	krognes steve e.	sold	-1,896,250	20.5	-92,500	-
Mar 29, 2024	watts ryan j.	gifted	-	-	-40,000	president and ceo
Mar 15, 2024	sato vicki l	sold	-33,486	20.1	-1,666	-
Feb 15, 2024	sato vicki l	sold	-30,604	18.37	-1,666	-
Feb 14, 2024	ho carole	sold	-24,994	17.79	-1,405	chief medical officer
Feb 14, 2024	schuth alexander o.	sold	-355,460	17.66	-20,128	cofo and secretary
Feb 13, 2024	watts ryan j.	sold	-165,794	17.29	-9,589	president and ceo
Feb 13, 2024	ho carole	sold	-48,135	17.29	-2,784	chief medical officer
Feb 13, 2024	schuth alexander o.	sold	-46,959	17.29	-2,716	cofo and secretary

Which funds bought or sold DNLI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	0.21	-52,699	1,207,540	-%
May 13, 2024	FMR LLC	added	92.09	11,521,500	25,291,300	-%
May 13, 2024	Nuveen Asset Management, LLC	added	59.09	3,573,060	10,428,200	-%
May 13, 2024	Rafferty Asset Management, LLC	added	35.08	2,014,790	8,924,330	0.03%
May 13, 2024	Fernwood Investment Management, LLC	new	-	102,600	102,600	0.03%
May 13, 2024	NEOS Investment Management LLC	new	-	444,217	444,217	0.03%
May 13, 2024	NOMURA ASSET MANAGEMENT CO LTD	sold off	-	-	-	-%
May 13, 2024	BANK OF MONTREAL /CAN/	new	-	881,282	881,282	-%
May 13, 2024	EverSource Wealth Advisors, LLC	unchanged	-	-	5,537	-%
May 13, 2024	E Fund Management Co., Ltd.	added	18.87	50,684	421,727	0.03%

Are Funds Buying or Selling DNLI?

Are funds buying DNLI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DNLI

No. of Funds

DNLI Alerts

Losses in recent quarter

Unveiling Denali Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	bratton douglas k	4.2%	5,750,882	SC 13G/A
Feb 13, 2024	vanguard group inc	7.84%	10,834,483	SC 13G/A
Feb 12, 2024	biogen inc.	75%	12,751,365	SC 13G/A
Feb 08, 2024	wellington management group llp	5.26%	7,274,717	SC 13G
Jan 30, 2024	baillie gifford & co	10.32%	14,260,724	SC 13G/A
Jan 30, 2024	temasek holdings (private) ltd	4.9%	6,895,992	SC 13G/A
Jan 25, 2024	blackrock inc.	8.4%	11,542,861	SC 13G/A
Mar 30, 2023	temasek holdings (private) ltd	5.0%	6,895,992	SC 13G
Feb 13, 2023	bratton douglas k	5.2%	7,000,882	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Denali Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 18, 2024	ARS	ARS
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	DEFA14A	DEFA14A
Apr 17, 2024	4	Insider Trading
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 29, 2024	4	Insider Trading

Peers (Alternatives to Denali Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	22.08%	-1.47%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.34%	-28.23%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-13.63%	-16.32%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	5.96%	-13.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	8.09%	95.42%	-9.93	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-20.37%	-53.19%	-11.99	9.55	394.93%	39.61%
AXSM	3.7B	251.0M	11.93%	-0.48%	-12.4	14.64	73.58%	-86.73%
ARWR	2.8B	240.7M	-7.33%	-42.62%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.36%	-32.87%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	8.34%	25.49%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	214.95%	66.21%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	4.53%	306.67%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.99%	24.13%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-6.93%	99.64%	-0.7	7.61	-13.45%	69.54%

Denali Therapeutics Inc News

Latest updates

Denali Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-	-	-	1.00	294	35.00	10.00	4.00	52.00	42.00	13.00	5.00	23.00	170	317	9.00	6.00	4.00	5.00	14.00	4.00	65.00
Operating Expenses	-0.2%	132	133	115	124	156	116	111	114	109	90.00	91.00	85.00	79.00	73.00	70.00	67.00	64.00	62.00	64.00	67.00	47.00
S&GA Expenses	-100.0%	-	25.00	25.00	26.00	27.00	24.00	23.00	21.00	23.00	22.00	19.00	19.00	19.00	18.00	16.00	14.00	13.00	11.00	11.00	15.00	9.00
R&D Expenses	-0.7%	107	108	90.00	98.00	129	92.00	88.00	93.00	86.00	68.00	72.00	66.00	60.00	55.00	54.00	53.00	51.00	52.00	53.00	52.00	37.00
Income Taxes	-100.0%	-	0.00	-	-	0.00	-0.01	-	0.00	-	-0.57	-	-	-	1.00	0.00	0.00	-0.10	0.00	-0.10	-0.30	-
Net Income	14.8%	-101	-119	-99.35	183	-109	-98.68	-103	-58.79	-65.22	-75.26	-84.59	-60.69	-70.04	245	-58.23	-58.76	-56.76	-54.02	-46.26	-58.34	-38.99
Net Income Margin	5.5%	-0.42*	-0.44*	-0.37*	-0.37*	-3.65*	-3.01*	-2.73*	-2.53*	-3.45*	-5.97*	0.25*	0.29*	-	-	-	-	-	-	-	-	-
Free Cashflow	-14.7%	-115	-100	-89.43	-119	-61.59	-77.51	-63.10	-45.79	-76.15	-68.55	-43.31	-54.99	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	37.0%	1,581	1,154	1,237	1,306	1,409	1,460	1,228	1,292	1,321	1,404	1,450	1,510	1,548	1,604	1,070	647	696	553	603	638	677
Current Assets	-8.5%	974	1,064	1,143	1,224	1,325	1,372	1,139	1,115	988	897	1,056	1,342	1,432	1,496	971	559	605	430	494	496	500
Cash Equivalents	-51.1%	62.00	127	148	132	68.00	218	120	157	106	295	396	487	437	509	353	139	209	81.00	83.00	63.00	40.00
Net PPE	2.8%	47.00	46.00	48.00	40.00	42.00	44.00	42.00	39.00	38.00	39.00	40.00	40.00	41.00	41.00	42.00	44.00	45.00	47.00	47.00	47.00	37.00
Liabilities	2.2%	126	123	118	119	443	418	416	408	403	442	438	437	443	454	188	145	151	158	165	162	160
Current Liabilities	5.9%	83.00	78.00	71.00	69.00	391	364	361	348	341	378	54.00	51.00	55.00	72.00	105	58.00	48.00	45.00	47.00	47.00	43.00
Shareholder's Equity	41.2%	1,455	1,031	1,118	1,187	967	1,042	811	884	918	962	1,012	1,073	1,105	1,151	883	502	545	395	438	475	517
Retained Earnings	-9.1%	-1,218	-1,116	-996	-897	-1,080	-970	-872	-769	-710	-645	-569	-485	-424	-354	-599	-541	-482	-425	-371	-325	-266
Additional Paid-In Capital	24.6%	2,673	2,145	2,114	2,084	2,048	2,019	1,694	1,664	1,636	1,608	1,581	1,557	1,529	1,504	1,480	1,041	1,025	819	808	798	782
Shares Outstanding	3.0%	143	138	138	137	137	136	123	123	123	122	122	121	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,000	-	-	-	1,500	-	-	-	2,800	-	-	-	851	-	-	-	716	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-15.2%	-113	-98.66	-87.36	-113	-58.80	-72.66	-57.05	-42.90	-72.11	-65.49	-41.43	-54.22	-50.24	514	0.00	-43.36	-54.49	-47.64	-30.43	-43.17	-30.32
Share Based Compensation	7.1%	28.00	26.00	27.00	27.00	28.00	25.00	25.00	24.00	26.00	22.00	21.00	21.00	21.00	14.00	13.00	12.00	11.00	9.00	9.00	14.00	7.00
Cashflow From Investing	-720.4%	-453	73.00	101	168	-92.71	-127	15.00	89.00	-117	-40.75	-53.01	98.00	-25.40	-367	-212	-30.41	-13.33	42.00	49.00	64.00	-8.05
Cashflow From Financing	10532.8%	500	5.00	2.00	9.00	2.00	300	5.00	4.00	1.00	5.00	3.00	7.00	4.00	10.00	426	3.00	196	2.00	1.00	3.00	1.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DNLI Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Collaboration revenue:

Collaboration revenue from customers

^[1]

$ 0

$ 35,141

Total collaboration revenue

35,141

Operating expenses:

Research and development

^[2]

107,016

128,816

General and administrative

25,236

27,140

Total operating expenses

132,252

155,956

Gain from divestiture of small molecule programs

14,537

Loss from operations

(117,715)

(120,815)

Interest and other income, net

15,913

11,034

Net loss

(101,802)

(109,781)

Other comprehensive income (loss):

Net unrealized gain (loss) on marketable securities, net of tax

(1,939)

4,369

Comprehensive loss

$ (103,741)

$ (105,412)

Net loss per share, basic (usd per share)

$ (0.68)

$ (0.80)

Net loss per share, diluted (usd per share)

$ (0.68)

$ (0.80)

Weighted average number of shares outstanding, basic (in shares)

149,404,188

136,524,528

Weighted average number of shares outstanding, diluted (in shares)

149,404,188

136,524,528

[1]	Includes related-party collaboration revenue from customers of $0.1 million for the three months ended March 31, 2023.
[2]	Includes expenses for cost sharing payments due to a related party of $4.2 million for the three months ended March 31, 2023.

DNLI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 60,574	$ 127,106
Short-term marketable securities	876,295	907,405
Prepaid expenses and other current assets	36,706	29,626
Total current assets	973,575	1,064,137
Long-term marketable securities	490,723	0
Property and equipment, net	46,863	45,589
Operating lease right-of-use asset	25,309	26,048
Other non-current assets	44,621	18,143
Total assets	1,581,091	1,153,917
Current liabilities:
Accounts payable	11,855	9,483
Accrued clinical and other research & development costs	19,956	19,035
Accrued manufacturing costs	16,720	15,462
Other accrued costs and current liabilities	5,986	5,152
Accrued compensation	8,053	21,590
Operating lease liability, current	7,512	7,260
Deferred research funding liability, current	12,500	0
Total current liabilities	82,582	77,982
Operating lease liability, less current portion	43,034	44,981
Total liabilities	125,616	122,963
Commitments and contingencies (Note 6)
Stockholders' equity:
Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.01 par value; 400,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 142,512,856 shares and 138,385,498 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	1,751	1,711
Additional paid-in capital	2,673,033	2,144,811
Accumulated other comprehensive income (loss)	(1,296)	643
Accumulated deficit	(1,218,013)	(1,116,211)
Total stockholders' equity	1,455,475	1,030,954
Total liabilities and stockholders’ equity	$ 1,581,091	$ 1,153,917

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

CEO	Dr. Ryan J. Watts Ph.D.
WEBSITE	denalitherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	438

Denali Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Denali Therapeutics Inc? What does DNLI stand for in stocks?

DNLI is the stock ticker symbol of Denali Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Denali Therapeutics Inc (DNLI)?

As of Tue May 14 2024, market cap of Denali Therapeutics Inc is 2.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DNLI stock?

You can check DNLI's fair value in chart for subscribers.

What is the fair value of DNLI stock?

You can check DNLI's fair value in chart for subscribers. The fair value of Denali Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Denali Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DNLI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Denali Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether DNLI is over valued or under valued. Whether Denali Therapeutics Inc is cheap or expensive depends on the assumptions which impact Denali Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DNLI.

What is Denali Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, DNLI's PE ratio (Price to Earnings) is -20.53 and Price to Sales (PS) ratio is 8.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNLI PE ratio will change depending on the future growth rate expectations of investors.